Introduction
To survive in the natural environment and compete with other microorganisms for resources, many bacteria produce antimicrobial compounds to inhibit or kill other competing strains, including human and animal pathogens. One subclass of these antimicrobial compounds is the antibacterial peptides, which can be divided into 2 categories based on the biosynthetic pathways by which they are generated. One group consists of gene-encoded, ribosomally synthesized peptides (bacteriocins) that typically have 30 to 60 residues, may be either unmodified or extensively post-translationally altered (i.e. lantibiotics), and are active against closely related bacteria (1,2,3). Peptides in the second class are non-ribosomal in origin and are produced by a series of condensations catalyzed by specific non-ribosomal peptide synthetases (NRPSs) 1 using a templated multienzyme mechanism (4, 5) . These NRPSs are large, multi-functional proteins composed of different modules, each of which has different domains capable of performing one step in the condensation of an amino acid onto a growing peptide chain (6) . The resulting peptidic compounds often contain non-proteinaceous amino acids, including D-amino acids, hydroxy acids, or other unusual constituents (7) . The peptide portion of antibiotics produced in this fashion is generally smaller than in ribosomal bacteriocins and usually has less than 20 amino acids (8) .
Our interest in bacteriocins from lactic acid bacteria, both unmodified (9,10) and multi-component, post-translationally modified lantibiotics (11) , has led us to examine other species of Gram-positive bacteria, such as Bacillus (12) , for novel peptidic antimicrobial agents. During a screening program we found that a Paenibacillus kobensis strain isolated from a soil/manure sample produced an active modified peptide with broad activity against both Gram-positive and Gram-negative organisms, including a number of human and animal pathogens. We now report that the structure of the principal antimicrobial compound formed by this strain, mattacin, is identical to polymyxin M, an uncommon antibiotic previously reported in the Russian literature (13,14,15,16 all reports in Russian) (figure 2). Although polymyxins represent one of the earliest classes of commercially important antibiotics to be identified (17) , and at least 15 unique polymyxins have been described (18) , only polymyxin B is currently widely used and studied. In addition to efficient production and purification of mattacin, the present study describes its NMR solution structure and transfer NOE determination of conformational changes which occur upon binding to lipid A, and compares these to previous results reported by others (19) with polymyxin B. Isothermal titration calorimetry (ITC) was also employed to compare the binding of mattacin and polymyxin B to lipopolysaccharide (LPS), the major antigen of the outer membrane of Gram-negative bacteria. Finally, the biological potency of mattacin was assessed in comparison to polymyxin B, and the biosynthesis of mattacin was briefly examined.
by guest on August 17, 2017 http://www.jbc.org/ Downloaded from indicator organism E. coli BF2 (.5 % inoculum). The molten agar was swirled gently and then dispensed in 20 ml aliquots onto sterile Petri plates, allowed to cool, and then stored at 4 ºC. When performing activity assays, small wells (4.6 mm diameter) were made in the seeded agar plates, and 50 mL aliquots of the solutions to be tested were dispensed into each well. The plates were then incubated at 30 ºC with growth of the indicator being visible within as a little as three hours.
Spectrum of Activity. The antimicrobial spectrum was determined using a deferred inhibition assay previously described by Ahn and Stiles (23) . Briefly, the producer strain was spotted onto TSA plates and incubated 24 hours at 30 °C. Molten 0.75% TSA, Luria Burtani (LB), or MRS soft agar (media used was optimum for each indicator strain) was then inoculated with 80 ml of a late log-phase indicator broth culture (approximately 10 6 viable cells/ml) and poured onto the surface of the plate containing the producer strain colonies. These agar overlays were then incubated overnight at either 30 °C or 37 °C (according to the indicator's optimum temperature), and the zones of inhibition were then measured. Alternatively, 10 ml of a purified, known-concentration antimicrobial peptide solution was spotted onto the surface of a TSA plate, allowed to dry, and overlaid as described above.
Antimicrobial Peptide Production During Growth and Arbitrary Unit Definition.
A fresh, overnight, producer strain culture (10 ml) was inoculated into 1 liter of TSB and incubated at 30 °C with stirring. At various time intervals during this incubation, 1 ml of culture was collected to determine growth phase and antimicrobial peptide production.
These samples were immediately centrifuged (14000 rpm, 20 min, 4 °C) to remove the cells. The supernatant was heat treated at 65 °C for 20 min to inactivate any protease activity. The activity of each supernatant was then determined using a two-fold dilution, agar diffusion test. The samples were serially diluted in 2-fold increments, and 20 ml of each dilution spotted onto a TSA plate. These spots were dried, and the plate overlaid and read as described above with E. coli BF2 as the indicator strain. An arbitrary activity unit (AU), defined as the 20 ml sample from the highest dilution that had a clear inhibition zone, was then determined for each fraction.
DNA Preparation and Transformation.
Plasmids from E. coli were isolated using the Qiagen Plasmid mini kit (Qiagen Corp., Valencia, CA) as described by the manufacturer's instructions. Plasmids from the producer strain were isolated using the method of Sambrook et al. (24) , except that cells were treated with 10 mg/ml of lysozyme for 30 min at 37 °C prior to the SDS lysis step. Transformation of E. coli Jm2r' was performed using CaCl 2 E. coli competent cell preparation according to the method of Sambrook et al. (24) , and transformation of the producer strain was performed with the transposon delivery plasmid pLTV3 (25) following the protocol of Dramsi et al (26) . The column was then washed with 30 % ethanol (500 ml). The active peptide was then removed from the Amberlite column by washing with 500 ml of 70 % acidisopropanol (pH 2 by addition of 1 M HCl). All fractions were assessed for activity using the well-plate assay described above. The active 70 % acid-isopropanol (pH 2) fraction was evaporated to dryness by rotary evaporation and the yellow residue was redissolved/suspended in 5.0 mL of purified (milli-Q system, Millipore, Bedford, Mass.)
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water. This concentrated solution was next applied to a column (2.5 x 50 cm) containing G25 superfine Sephadex (Amersham Pharmacia, Uppsala, Sweden) at a flow rate of 1.0 ml/min. The column was eluted with purified (milli-Q) water overnight and 10 ml fractions were collected. Each fraction was again assayed for activity as described above.,
The active fractions 17-20 were then pooled, evaporated, and redissolved in 10 ml of 20% isopropanol in preparation for reverse phase HPLC. Complete isolation of mattacin required 2 separate HPLC methods both employing a C 18 steel-walled column (Vydac, 10
x 250 mm, 5 mm). During the initial HPLC work, all isolatable peaks were assessed for antimicrobial activity using the aforementioned well-plate assay until the retention time of mattacin was well established. In the first method, a 1.0 ml injection was applied and a gradient of water and isopropanol (0.1% TFA), starting at 20 % and climbing to 30 % isopropanol over 25 min, was used (flow rate = 2.5 ml/min, detection at 225 nm). Using this method, most of the polar impurities were removed with mattacin eluting in a broad peak (R t =18-20 min) somewhat later. The active fractions were pooled, evaporated to dryness, and redissolved in 6.0 ml of 45 % methanol. The second method employed the same C 18 column using a gradient of water and methanol (0.1% TFA), starting at 45 % and climbing to 60 % methanol over 15 min (flow rate = 4.0 ml/min, detection at 225 nm). Under these conditions, mattacin was isolated as a single peak (R t = 10-11 min). Using 1.0 ml sample injections, the entire sample was purified, and after pooling, evaporation of the methanol, and lyophilization, as much as 5 mg of pure mattacin was obtained as white powder from a 1 liter culture.
Amino Acid Analysis. Mattacin (100 mg) was hydrolyzed at 160 °C for 1 h with 100 mL 5.7 M HCl/0.1 % phenol in a sealed, evacuated tube. The solvent was removed by vacuum centrifugation (Speed-Vac), and the dried hydrolysate was redissolved in 0.2 M sodium citrate buffer (pH 2.0). Analysis was achieved through cation-exchange chromatography with a Beckman 6300 amino acid analysis instrument using a 120 x 2.5 mm ID column with post-column detection/quantitation by reaction with ninhydrin at 135°C .
Acetylation of Mattacin.
With the knowledge that mattacin contained threonine, it was hoped that a crystalline product, suitable for x-ray analysis, might be obtained by chemically modifying nucleophilic residues,. To this end, 500 mg of mattacin was treated with 1.0 ml of pyridine/acetic anhydride (1:1) on ice. The mixture was allowed to warm to room temperature, and after 4 h a small aliquot (10 ml) was removed for mass spectrometric analysis.
Mass Spectroscopy. Samples for MALDI mass analysis were prepared using sinnapinic acid as matrix. Solutions containing the sample peptide were mixed in even part with a stock solution of sinnapinic acid (10 mg/ml) in 60 % acetonitrile (0.1 % TFA). A thin layer of sinnapinic acid was deposited on the surface of the gold target plate by delivery of a small droplet (0.7 ml) of a solution containing sinnapinic acid (4 mg/ml) in 50 % acetone/50 % methanol. After evaporation of the acetone/methanol, a 0.3 ml droplet of the solution containing the sample peptide-matrix mixture was deposited on top of the fresh matrix layer on the plate. The solvent was evaporated at 1 atm prior to analysis.
Mass spectra were recorded with a single-stage reflectron, MALDI-TOF mass spectrometer (Applied BioSystems (Foster City, CA) API QSTAR Pulsar with an oMALDI source) (27) . Tandem MS/MS was performed using two different instruments. The QSTAR instrument, described above, was of the geometry QqTOF, where MS/MS analysis was achieved through collision-induced dissociation (CID) in the rf-only section of the mass spectrometer (Q 2 ) after mass selection with the Q 1 resolving quadrupole.
Fragment ions were detected in the orthogonal time-of-flight section of the mass spectrometer. Ion generation was achieved through MALDI ionization using sinnapinic acid as the matrix. The QSTAR was equipped with a 20 Hz pulsed nitrogen laser operating at 337 nm. CID MS/MS analysis was completed using argon as the collision Table I , revealed the bacterium to be P.
kobensis, later named strain M.
Spectrum of Activity. Live-cell deferred inhibition assays showed that P. kobensis M inhibited numerous Gram-positive and Gram-negative species including among others E.
coli O157:H7 ATCC 33150, Salmonella Rubislaw, and Listeria monocytogenes, but failed to inhibit Pediococcus acidilactici. Purified mattacin and polymyxin B showed the same inhibition spectrum as the live P. kobensis M cells with the exception that they both failed to inhibit the strains of Listeria and Bacillus tested. Furthermore, mattacin showed a consistently higher level of activity against all strains tested in this study, including activity against Vibrio parahaemolyticus G1-166, against which Polymyxin B was inactive. Table III shows the complete antimicrobial spectrum elucidated in this study as well as the inhibition spectrum of polymyxin B against the same organisms for comparative purposes.
Antimicrobial Peptide Production During Growth. Figure 3 shows the relationship between P. kobensis M growth and antimicrobial peptide production. As can be seen from this figure, production started at the exponential phase and reached its highest point during the stationary phase.
Transpositional Mutagenesis of Mattacin Biosynthetic Genes.
To identify the genes related to polymyxin M production, we performed transposon insertional mutagenesis with Tn917. Transformation of P. kobensis M with the plasmid pLTV3 produced seven transformants, of which one was used to produce our insertional mutagenesis library.
Nine partial production mutants and one non-production mutant were obtained from a screen of approximately 7,000 colonies. PCR amplification of these mutants revealed all to contain the Tn917 transposon sequence with the wild-type producer strain lacking any endogenous transposon sequence. Plasmid sequencing from the resultant E. coli Jm2r'
transformants showed a variety of homologies to known genes as summarized in Table II . 
Discussion
In recent years a large number of antimicrobial peptides from Gram-positive bacteria have been discovered, including ribosomally produced bacteriocins (36, 37, 38) .
The non-ribosomally generated polymyxins represent one of the earliest classes of structurally unique peptide antibiotics to be identified (17) . Paenibacillus spp. are Grampositive, spore-forming bacteria from which polymyxins have been isolated and their in vitro biosynthesis by cell-free enzyme systems has been successfully demonstrated (39) .
Although the first member of the polymyxin family, polymyxin B, was discovered in 1947 (17) , the genetic control of their biosynthesis has not been described. We utilized the Tn917 transposon to study the mattacin (polymyxin M) biosynthesis genes and screened approximately 7,000 colonies for production mutants.
The majority of the production mutants exhibited decreased levels of production as opposed to a complete loss of production. This is not consistent with other studies using Tn917 for iturin and fengycin biosynthesis genes (40, 41) . In those studies, the It was in this region of the heptacycle that the greatest conformational variation in the two models was observed, and it seems reasonable to suggest that the significantly diverse hydrophobic/hydrophilic residues present in the two peptides contribute to these differences.
To ascertain whether mattacin behaved in a manner similar to polymyxin B in its interaction with LPS, isothermal titration calorimetry (ITC) was employed. The thermodynamics of polymyxin B binding to LPS have been previously investigated using ITC by the group of Surolia (34) . In these studies, a highly processed LPS preparation from E. coli was used (extensive treatments with proteases, chelating agents, and purifications via dialysis and size exclusion chromatography). Using these conditions, Results from the activity assays for both mattacin and polymyxin B showed that the two peptides have virtually indistinguishable spectra of activity. Mattacin did appear to be slightly more active in most cases, but these differences are not very significant (less than an order of magnitude). An interesting observation in the activity assays was that all strains of Listeria and Bacillus were inhibited by the live cells of P. kobensis M, but the purified polymyxins B and M had no effect. This suggests that another compound(s) is produced by this organism which is either lethal to Listeria and Bacillus on its own, or acts in synergy with another compound(s), possibly the polymyxin, to elicit its killing effects. 
